ClinicalTrials.gg
RecruitingNCT07295834MFIUpdated Nov 20, 2026

Modafinil For Fatigue in IBD

A Phase 2 interventional study of Modafinil and Placebo in Crohn Disease (CD), Ulcerative Colitis (UC) and Fatigue, sponsored by Imperial College London. Recruiting at 4 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Imperial College London · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Nov 20, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 217 studies in Crohn Disease with a site in United Kingdom — 47 open to participants now, 66 under way, 26 of them phase 3. Crohn Disease · United Kingdom.

Planned enrollment
122nd of 171
70 · median 168
Started
2026
with 8 others
Phase 2
44 of 217
6 open now
Primary completion
2027-12
later than 33 of 65 live
Registered
207th of 217
by date

Among the 217 studies in Crohn Disease with a site in United Kingdom, this one is the 122nd largest by planned enrollment of the 171 interventional ones that give a count, is one of 9 that started in 2026, is one of 44 in phase 2, reaches primary completion later than 33 of the 65 other live ones, and was the 207th registered.

Crohn Disease

1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

47 of the 217 studies in Crohn Disease with a site in United Kingdom are open now. Recruiting first, the newest first:

41 more — sign in →

All 47 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 217 studies in Crohn Disease with a site in United Kingdom, or all of them as a file.
02

Study summary

Fatigue is a big problem in people with inflammatory bowel disease (IBD). Even when IBD is well controlled, 50% of patients remain fatigued most of the time. Fatigue can be physical (e.g. feeling tired or weak) and mental (e.g. brain fog). However, there are no effective treatments for IBD fatigue.

Modafinil is a medication that can rapidly improve fatigue. It usually acts within 30 minutes and improves wakefulness. It can also improve brain fog. Modafinil has been used for over 30 years in people with narcolepsy, which is a condition where people fall asleep during the day. Modafinil has also been used in people who do not have narcolepsy.

This study will compare modafinil with a dummy tablet (placebo) in people with IBD. This is a feasibility study. This means it primarily aims to test whether a trial like this can be conducted in people with IBD.

Half of the patients in the study will receive modafinil and half will receive placebo. Treatment will be 12 weeks. Patients will start by taking 1 tablet and will then increase to 2 tablets and then 3 tablets if needed. A computer will randomly allocate treatment, meaning there is an equal chance of being allocated modafinil or placebo. They will be followed up after 6 weeks and 12 weeks.

Being a feasibility study, the investigators will measure how many patients consent to the study; how many complete treatment; and how acceptable the treatment is. Participants will complete a range of questionnaires measuring fatigue, mental health and gut health, primarily to look at the completeness and spread of data, and to obtain estimates of treatment effects and their variance.

If feasible, this study will support a larger version of the trial.

Read the detailed description

Design: The current study is a randomised controlled trial (a study in which people are allocated by chance to receive different interventions). The trial will compare mirtazapine against a placebo (dummy) tablet in 70 patients with both severe fatigue and IBD. This is a feasibility study, meaning that it is testing whether it will be possible to do a larger version of this study.

Setting: Consent and assessments will take placebo in clinic rooms or clinical research facilities at Imperial College Healthcare National Health Service (NHS) Foundation Trust, King's College Hospital, St Mark's Hospital and Guy's and St Thomas' Hospital, or online if the patient prefers this. The latter is important in maximising participation to the study for participants who may find it difficult to access hospitals, which is a common problem in inflammatory bowel disease (IBD) due to issues like pain and incontinence.

Recruitment: Consecutive patients aged ≥18 with diagnosed IBD and significant fatigue will be identified from outpatient clinics and biologics infusion suites. If possible, clinicians will use the IBD Fatigue Scale to identify people scoring ≥11. If necessary, patients will be identified from screening of endoscopy schedules and IBD multidisciplinary team meetings. The clinical team will seek the patient's permission to be contacted by the research team.

If they agree, the research team will then contact the patient - either in the clinic or over the phone - and provide the patient information sheet. The research team will check some basic pre-screening questions: confirming IBD diagnosis, duration of fatigue, whether they are planned to change any IBD treatments in the next 12 weeks, and the 5- question IBD Fatigue Assessment Scale if not already completed. Before pre-screening, the research team will advise patients that the fatigue information they provide will be passed onto their clinical team - with their permission - even if they decide not to take part in the study. They will be advised that any other information about their IBD will not be retained by the study team if they do not wish to take part. If anyone has an elevated fatigue score but does not wish to take part in the study, the research team will seek the patient's permission to relay the fatigue score to their clinical team.

Those who are deemed to be potentially eligible after pre-screening will be invited for a full screening assessment with a member of the study team. Final study inclusion and consent will be taken by a study doctor.

Study procedures: There will be 4 main study visits. At the first visit, the researcher will explain the study in detail. They will answer any questions the participant has. They will ask the participant some brief questions about their mental health and gut health. They will complete the IBD Fatigue Scale if not already done to ensure they score ≥11/20. The research team will confirm that their fatigue is at least 6 months in duration. If eligible according to screening criteria, the research team will invite them to participate and to sign a consent form.

The researchers will check that the participant meets all the inclusion criteria and none of the exclusion criteria. They will ask the participant more detailed questions about fatigue and mental health (the National Institute for Health and Care Excellent (NICE) criteria for chronic fatigue syndrome, Mini Neuropsychiatric Interview for depression) and will complete further questionnaires lasting around 20 minutes. They will also be asked to have height and weight measured and to provide a blood sample (though these are not compulsory). They will have their hand grip strength tested. If female and of childbearing age, the researcher will take a blood pregnancy test. If they are eligible to take part, the participant will then be randomised by computer to one of the 2 treatments (modafinil or placebo). The tablets for both groups are made to look the same. Neither participant nor the research team will know in which treatment group they are allocated to.

Participants will be given medication the same day or will receive it via recorded post.

The 2 treatment arms are:

  1. Modafinil (a stimulant medication) If randomised to this group, the participant will be asked to take a modafinil capsule once in the morning. If their fatigue does not improve much, they can add a second tablet after 2 weeks. If needed, they can then add a third tablet after 4 weeks. The total treatment lasts 12 weeks.
  2. Placebo If randomised to this group, the participant will take a placebo tablet once per day for 12 weeks. If their fatigue does not improve much, they can add a second tablet after 2 weeks. If needed, they can then add a third tablet after 4 weeks. The total treatment lasts 12 weeks. Participants will not know which treatment (modafinil or placebo) they are taking.

The participant will meet with the research team again at 6 and 12 weeks after starting treatment. This can be in person or online. These appointments will last for around 30 minutes and will involve:

  • Repeating most of the questionnaires completed at the beginning
  • A review of general health and other medications
  • Repeat blood tests and weight measurement (12 weeks only)
  • Repeat hand grip strength measurement (12 weeks only)

Although they will finish treatment after 12 weeks, the investigators will participants whether they can attend a final visit 6 weeks later. This is not compulsory. It will involve repeating most of the questionnaires. Throughout, participants will still be able to access any talking therapies for depression or fatigue, though should not start any other antidepressants.

Progression criteria: The milestones for progression to a full efficacy clinical trial will be based on the proportion-to-target of patients randomised overall; % completing 12 weeks of treatment; % of participants taking at least 75% of prescribed mediation; % of planned data and samples collected at 12 weeks; and % participants describing the treatment as acceptable (≥6/10 on 0-10 scale).

Sample size: As a feasibility study, power calculations for a treatment effect are not applicable. The investigators will recruit 70 participants (35 per group), which is sufficient to generate robust variance estimates. Based on 70 patients and an anticipated follow-up rate of 80%, a two-sided confidence interval will extend no more than 12% of the observed proportion.

Data management:

Data will be collected on paper case report form (CRF) and then transferred to an electronic case report form (eCRF). The type of activity that an individual user may undertake is regulated by the privileges associated with his/her user identification code and password. All forms and tapes related to study data will be kept in locked cabinets. Access to the study data will be restricted. The database will be password-protected.

Statistical methods:

A statistical analysis plan (SAP) will be approved by the Trial Steering Committee independent statistician. The analysis population will use intention-to-treat principles. A recruitment plot of predicted vs. actual recruitment will be generated on a monthly basis.

Participant flow through the study will be presented. Descriptive data will be presented in the form of means and standard deviations; medians and ranges; or percentages with 95% confidence intervals, as appropriate depending on the data being described. The investigators will use linear mixed models to estimate the between group adjusted mean difference (aMD) between mirtazapine and placebo groups at week 12 after adjustment for baseline scores, time, and a treatment-by-time-interaction. Associated 95% confidence intervals will be presented alongside the aMD without p-values. More details will be provided in the statistical analysis plan.

Timeline: This 24-month study includes up to 5 months for setup and approval, 12 months for recruitment (plus 3 months' contingency), 4 months for follow-up visits (including post-treatment follow-ups) and 3 months for write-up and dissemination.

03

Conditions studied

  • Crohn Disease (CD)
  • Ulcerative Colitis (UC)
  • Fatigue

Keywords

  • Crohn's Disease
  • Fatigue
  • Ulcerative Colitis
  • Modafinil
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Established diagnosis of Crohn's disease (CD) or ulcerative colitis (UC) according to clinical notes
  2. Reported fatigue duration of 6 months or more
  3. Aged 18 years or over
  4. Current IBD Fatigue Assessment Scale score ≥11/20
  5. Use of if female and of childbearing age. Female participants of childbearing age will require a negative serum/urine pregnancy test before starting the study and will also need to agree to use an acceptable form of contraception throughout the intervention period, e.g. long-acting reversible contraceptive.
  6. Faecal calprotectin \<250mcg within the last 3 months
  7. Normal concentration (≥130g/L [men] and ≥120g/L [women]) within the last 3 months
  8. Thyroid stimulating hormone (TSH) level (0.4-4.0 mU/L) within last 3 months
  9. Serum total B12 concentration (≥180 nanograms/L) within last 3 months
  10. Able to provide written to enter the trial.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of drug or alcohol dependence syndrome according to patient report or GP record.
  2. Diagnosis of any dementia according to patient report or GP record.
  3. Diagnosis of psychosis or schizophrenia according to patient report or GP record.
  4. Diagnosis of bipolar disorder according to patient report or GP record.
  5. Current active suicidal ideation on clinical assessment by study psychiatrist.
  6. Current treatment with stimulant medication (e.g. methylphenidate), dopamine agonist (e.g. ropinirole), levo-dopa (L-DOPA), antipsychotic (e.g. olanzapine), avacopan, avaritinib, bosutinib, doravirine, grazoprevir, leniosilib, moboceritinib, Osimertinib, sofosbuvir, velpatasvir or voxilapravir
  7. to the administration of modafinil, as per the current SmPC.
  8. Patient-reported to modafinil
  9. Non-registration with a GP or failure to consent to sharing of the GP summary care record and any psychiatric assessments held.
  10. Currently enrolled in another drug trial or psychological therapy trial.
  11. Currently hospitalised for the treatment of IBD.
  12. Currently being prescribed a course of budesonide or reducing course of prednisolone for IBD.
  13. Planned change in IBD treatment within the next 12 weeks.
  14. Currently breastfeeding, pregnant or planning pregnancy.
  15. Diagnosis of indeterminate colitis
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
70 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    1 capsule, increasing if needed after 2 weeks to 2 capsules, increasing if needed after 2 weeks to 3 capsules. Total treatment duration 12 weeks.

    Drug: Placebo

  • Active comparator
    Modafinil

    1 x 100mg, increasing if needed after 2 weeks to 2 x 100mg, increasing if needed after 2 weeks to 3 x 100mg. Total treatment duration 12 weeks.

    Drug: Modafinil

Interventions

  • 100-300mg daily according to patient response

  • DrugPlacebo

    1-3 placebo capsules according to patient response

06

What researchers measure

Primary outcomes

  1. Recruitment rate

    Participants randomised overall, percentage of target

    Time frame: 2 years

  2. Trial adherence

    Percentage of participants completing 12 weeks of treatment

    Time frame: 12 weeks

  3. Treatment adherence

    Percentage of participants taking at least 75% of prescribed mediation

    Time frame: 12 weeks

  4. Study procedures acceptability and compliance

    Percentage of planned data and samples collected at primary endpoint (12 weeks)

    Time frame: 12 weeks

  5. Overall acceptability

    Percentage of participants describing the treatment as acceptable (≥6/10 on 0-10 scale)

    Time frame: 12 weeks

Secondary outcomes

  1. First 5 questions of the Inflammatory Bowel Disease-Fatigue questionnaire

    Range 0-20, higher scores indicate worse fatigue

    Time frame: 12 weeks

  2. Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) scale

    Range 0-52, higher scores indicate less fatigue

    Time frame: 12 weeks

  3. Patient Health Questionnaire-9

    Range 0-27, higher scores indicate worse depression

    Time frame: 12 weeks

  4. Generalised Anxiety Disorder-7

    Range 0-21, higher scores indicate worse anxiety

    Time frame: 12 weeks

  5. Maudsley 3-item Visual Analogue Scale

    Range 0-300, higher scores indicate worse depression

    Time frame: 12 weeks

  6. Pittsburgh Sleep Quality Index

    Range 0-21, higher scores indicate worse sleep

    Time frame: 12 weeks

  7. Euroqol 5-dimension quality of life questionnaire (EQ-5D-5L)

    Range 0-1, higher scores indicate better quality of life

    Time frame: 12 weeks

  8. Harvey Bradshaw Index (Crohn's disease patients only)

    Higher scores indicate worse disease activity

    Time frame: 12 weeks

  9. Simple Clinical Colitis Activity Index (ulcerative colitis patients only)

    Higher scores indicate worse disease activity

    Time frame: 12 weeks

  10. Inflammatory Bowel Disease Control Questionnaire

    Range 0-16, higher scores indicate better disease activity

    Time frame: 12 weeks

  11. Hand grip strength

    Range 0-100kg, higher scores indicate better hand grip strength

    Time frame: 12 weeks

07

Study locations

4 of 4 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Dec 2027, 18 months after the start.

Of 84 phase 2 interventional studies under Crohn Disease, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's planned 18 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Feb 2026 → May 2026, on Nov 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2025
First posted
Dec 22, 2025
StartActual
May 5, 2026was Feb 2026
Primary completionEst.
Dec 1, 2027
CompletionEst.
Feb 1, 2028
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 20, 2026
Sites
4 sites changed recruiting status (4 now recruiting)
Show 4 sites
  • Imperial College Healthcare NHS Trust · London, United Kingdomno status→Recruiting
  • St Mark's Hospital · London, United Kingdomno status→Recruiting
  • Guy's and St Thomas' NHS Foundation Trust · London, United Kingdomno status→Recruiting
  • King's College Hospital NHS Foundation Trust · London, United Kingdomno status→Recruiting
Nov 20, 2026
Start date
Feb 1, 2026→May 5, 2026 (actual)
Nov 20, 2026
Contact
Study contact changed: e•••@nhs.net→h•••@imperial.ac.uk. See the current contact
Nov 20, 2026
Title
Modafinil For Fatigue in IBD: A Feasibility Randomised Controlled Trial
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Not yet recruiting→Recruiting
    4 sites changed recruiting status (4 now recruiting)
    Show 4 sites
    • Imperial College Healthcare NHS Trust · London, United Kingdomno status→Recruiting
    • St Mark's Hospital · London, United Kingdomno status→Recruiting
    • Guy's and St Thomas' NHS Foundation Trust · London, United Kingdomno status→Recruiting
    • King's College Hospital NHS Foundation Trust · London, United Kingdomno status→Recruiting
    Start date Feb 1, 2026→May 5, 2026 (now actual)
    Contact Study contact changed: e•••@nhs.net→h•••@imperial.ac.uk. See the current contact
    Title Modafinil For Fatigue in IBD: A Feasibility Randomised Controlled Trial
    + 2 other changes: verification date and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07295834
Collaborators
Guy's and St Thomas' NHS Foundation Trust, King's College Hospital NHS Trust, Imperial College Healthcare NHS Trust, London North West University Health Care NHS Trust
Responsible party
Sponsor
First posted
Dec 22, 2025
Start date
May 5, 2026
Primary completion
Dec 1, 2027 (estimated)
Completion
Feb 1, 2028 (estimated)
Last update
Nov 20, 2026

Study contacts

Calum Moulton, MA MRCP MRCPsych PhD
Contact
calum.moulton@nhs.net
+44 07384 799297
Hannah Thomas, PhD
Contact
h.thomas1@imperial.ac.uk
Calum Moulton
principal investigator · Imperial College London

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Modafinil

Start the discussion